Background {#Sec1}
==========

Globally, primary liver cancer accounts for 6% of all cancers and 9% of all death from cancer. It is the sixth most common cancer and the second leading cause of cancer death. The important primary liver cancers include hepatocellular carcinoma (HCC), accounting for approximately 75%, and cholangiocarcinoma, accounting for approximately 6%. Although either surgical resection or liver transplant can be used for the treatment of liver cancer, limitations are caused by high recurrence rates after resection and low-ratio eligibility for surgery and transplant because this cancer is often detected at a late stage \[[@CR1], [@CR2]\]. In the tumor microenvironment, cancer cells and host immune responses interact to promote or inhibit the pathologic progression of cancer. The immune system can identify cancer cells, and mobilizing the immune response is able to eliminate cancer \[[@CR3]\]. Immunotherapy has emerged as a promising therapy and is being investigated in various tumors including liver cancer \[[@CR4]\]. Emerging evidence supports that the blockade of immune checkpoints is among the most promising approaches in cancer immunotherapy \[[@CR4]--[@CR6]\].

The activity of the immune system is mostly regulated by immune cells called T cells. In the tumor microenvironment, T cells can recognize tumor antigens, which are presented to T cell receptors by antigen-presenting cells (APCs). Besides signal via T cell receptors, T cell response is fine-tuned by a group of cell surface molecules, named immune checkpoints. They can be either stimulatory or inhibitory, and participate in various stages of T cell response (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR6]--[@CR11]\]. Many cancers are able to evade the immune system, mainly by overexpressing inhibitory ligands to damp T cell attack. As a result, fewer, and damaged T cells were found in patients with HCC, which contributed to the progression of this cancer \[[@CR12]\].Fig. 1Illustration of stimulatory and inhibitory immune checkpoints between T-cells, APCs, and cancer cells. Blockade of inhibitory immune checkpoints can positively regulate T-cell activation and prevent immune escape of cancer cells within the tumor microenvironment. Activation of stimulatory immune check points can augment the effect of immune checkpoint inhibitors in cancer therapeutics. Red, inhibitory immune checkpoints; blue, stimulatory immune checkpoints

Recently, in vitro and in vivo results show histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi), two important epigenetic drugs, can up-regulate expression of inhibitory immune checkpoints in either immune or cancer cells \[[@CR13]--[@CR15]\]. Epigenetic modifiers function importantly in priming and enhancing the therapeutic effect of the host immune system on cancer \[[@CR14], [@CR15]\]. The purpose of this review is to give a brief overview of the role for immune checkpoints related to liver cancer progression. It also provides new insights into the epigenetic mechanism in checkpoint immunotherapy and checkpoint blocking -- based therapeutic approaches for treatment of liver cancer.

Immune checkpoints and hepatocellular carcinoma {#Sec2}
===============================================

The most ex vivo studied and clinically relevant checkpoint proteins are CTLA-4, PD-1, and PD-L1 (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). The expression of inhibitory immune checkpoints can be dysregulated in a tumor microenvironment, which can lead to improvement of T cell-mediated immune response through cancer immunotherapy \[[@CR16]\]. The PD-1 pathway is found to suppress T cell activation mainly within peripheral tissues at the later phase, whereas the CTLA-4 pathways are involved in regulation of T cell-mediated immune responses primarily in lymph nodes at the priming phase \[[@CR17]\].Table 1Immune checkpoints expression in liver cancersCancer typeNumberTNM Stage (I + II / III + IV)Tumor differentiation (I + II / III + IV)Tumor size (cm)Immune checkpointsCellular expressionYearReferenceHuman HCC217 (tumor samples)Operable, resected101 (46%)/ 116 (53%)7.26 (1.0--2.5)PD-L1/PD-1neoplastic and inflammatory cells2016\[[@CR24]\]Human HCC17697/52112/645.3 (PD-L1 ~low~)/4.9 (PD-L1 ~high~)PD-L1CD68+ macrophages2016\[[@CR27]\]Human HCC90Operable, resected73/174.2 (1.3--15)PD-L1peritumoral hepatocytes2017\[[@CR25]\]Human HCC29459/87140/6110(\<5) /36(≥5)PD-L1/PD-1 and CTLA-4tumor infiltrating2017\[[@CR26]\]Human HCC6935/3450/197/21(Tim-3 low)/17/24 (Tim-3 high)Tim-3CD14+ monocytes2015\[[@CR28]\]Human HCC171100/71NR98/73PD-1 and Tim-3neoplastic and inflammatory cells2016\[[@CR29]\]Human ICC319/2213/1820 (\<5) / 11 (\>5)PD-L1 and PD-1neoplastic and inflammatory cells2009\[[@CR38]\]Human ICC2716/1119/8NRPD-L1ICC cells2016\[[@CR36]\]*HCC* hepatocellular carcinoma, *ICC* Intrahepatic cholangiocarcinoma, *NR* not reportedTable 2Pre-clinical studies with immune checkpoints in therapy of liver cancersCancer typeNumberTNM Stage (I + II / III + IV)Tumor differentiation (I + II / III + IV)Tumor size (cm)Immune checkpointsTherapyTarget cellsYearReferenceHuman HCC7157 / 1458 / 1336 (≤5) / 35 (\>5)PD-L1 and PD-1PD-L1and PD-1 antibodiesKupffer cells and CD8^+^ T cells2009\[[@CR23]\]Human HCCNRNRNRNRPD-L1Specific shRNA for PD-L1 and DNMT1HCC cell lines2017\[[@CR57]\]Human HCC3122/921/109(≤5) /22(\>5)CTLA-4CTLA-4 antibodiesTumor-Associated Antigen-Specific T Cells2011\[[@CR16]\]Mice HCCNRNRNRNRCTLA-4CTLA-4 antibodiesRegulatory T cells2017\[[@CR21]\]Human HCC5954 / 4 unknown, *n* = 1NRNRLAG3, PD-1, Tim3 and CTLA4Blocking antibodies to LAG3, PD-1, TIM3 or CTLA4tumor-infiltrating T cells2017\[[@CR30]\]Human HCC218/13NRNRGITRGITR ligandtumor-infiltrating Tregs2013\[[@CR33]\]*HCC* hepatocellular carcinoma, *ICC* Intrahepatic cholangiocarcinoma, *NR* not reported

CTLA-4 {#Sec3}
------

CTLA-4 is a CD28 homolog and primarily located in intracellular compartments in resting naive T cells. CTLA-4 inhibits T cell response by directly delivering an inhibitory signal to T cell, and interfering with the binding between B7 and CD28 \[[@CR18]\]. In 31 HCC patients, it was found the addition of anti-CTLA-4 antibody resulted in an increase in the frequency of tumor-associated antigens (TAA)-specific cytotoxic T cells in 60% of HCC patients, accompanied with enhanced antitumor effect of tumor-specific T cells \[[@CR19]\]. In addition, CTLA-4 is shown to be important for regulatory T cell (Treg) function. Tregs control functions of the effector T cells, and thus crucially maintain peripheral tolerance \[[@CR20]\]. Unlike effector T cells, Tregs constitutively express CTLA-4 to exert their immune suppression \[[@CR21], [@CR22]\]. Treg-specific CTLA-4 deficiency was shown to affect in vivo Treg suppressive function and promote tumor immunity \[[@CR21], [@CR22]\]. In a rat liver transplantation model with tumor recurrence, hepatic expressions of CTLA-4, TGF-β and PD-L1 were increased in the tumor tissues from small-for-size liver graft group compared to whole graft group. The results suggested that up-regulation of CTLA-4 may mediate the mobilization of Tregs by small-for-size graft injury, contributing to HCC recurrence after liver transplantation \[[@CR23]\]. HCC-derived Tregs down-regulated CD80/86 expression on splenic DCs in a CTLA-4 dependent manner, and inhibition of CTLA-4 could prevent the Treg-mediated suppression in anti-tumor immune responses \[[@CR24]\]. Thus, CTLA-4 could not only enhance the antitumor effect of effector T cells but also maintain self-tolerance and the suppressive function of Tregs in liver cancer immunity.

PD-1/PD-L1 {#Sec4}
----------

PD-L1 is the main ligand for PD-1, which is crucial for tumor immunity. In addition, PD-L1 also interacts with B7-1 to inhibit T cell immunity, and the role of this interaction in cancer immunity is still unclear \[[@CR25]\]. Binding of PD-L1 to its receptor can suppress T cell migration, proliferation, and secretion of cytotoxic mediators, and thus blocks the "cancer immunity cycle" \[[@CR26]\]. In the HCC tumor microenvironment, PD-L1 expression is mainly expressed in Kupffer cells but is slightly expressed on other APCs or HCC tumor cells \[[@CR27]\]. CD8+ T cells and Kupffer cells in human HCC tumor tissues expressed high levels of PD-1 and PD-L1, respectively. PD-L1+ Kupffer cells interact with PD-1 + CD8+ T cells and contribute to dysfunction of effector T cells in HCC. Elevated PD-L1 expression in HCC is indeed associated with poorer prognosis in HCC patients \[[@CR27]\]. In 217 HCCs, PD-L1 was expressed by both neoplastic and intra-tumoral inflammatory cells, which are related to tumor aggressiveness. It also suggests that the PD-L1/PD-1 immune checkpoint could be targeted in the treatment of particular HCC variants \[[@CR28]\]. More recently, 90 HCC patients with PD-L1 expression in peritumoral hepatocytes were demonstrated to have a significantly higher risk of cancer recurrence or metastasis and cancer-related death \[[@CR29]\]. Immunohistochemistry data in 294 HCC tissue samples showed PD-1 and PD-L1 expression was significantly related to high CD8+ tumor-infiltrating lymphocytes (TILs). Only high Edmondson--Steiner grade was markedly related to high PD-1 expression. High PD-L1 expression was demonstrated as an independent poor prognostic factor for disease-free survival in the high CD8+ TILs group. Further, combined high expression of PD-L1 and CD8+ TIL is an important prognostic factor related to the immune checkpoint pathway in HCC. Also, this result would be helpful in evaluating the applicable group of PD-1/PD-L1 blocking agent for HCC patients \[[@CR30]\]. PD-L1 expression was significantly increased in tumors with a high number of tumor-infiltrating lymphocytes (*ρ* = 0.533, *p* \< 0.001). High PD-L1 expression was associated with significantly shorter overall survival \[[@CR31]\]. These clinic data further support that PD-L1 is an important mediator in the progression and an important target in the anti-tumor therapy for liver cancer.

Other inhibitory checkpoints {#Sec5}
----------------------------

Several other inhibitory receptors, including T-cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) and LAG-3, are also upregulated on TAA-specific CD8+ T-cells in various cancer types, and are also involved in progression of liver cancer. Tim-3 is strongly expressed on CD4+ and CD8+ T-cells obtained from HCC lesions in contrast to the surrounding liver tissue. Tim-3 is expressed on tumor-associated macrophages (TAM), which contributes to HCC growth \[[@CR32]\]. Intriguingly, a high number of Tim3+ tumor infiltrating cells and Tim3+ TAM in HCC lesions are associated with a poor prognosis \[[@CR33]\]. In 171 patients with hepatitis B virus (HBV)-related HCC, both PD-1 and Tim-3 expressions in liver infiltrating lymphocytes were significantly high in tumor tissues compared to tumor adjacent tissues. The up-regulation of PD-1 and Tim-3 were related to higher tumor grades \[[@CR33]\]. There is a significant positive intercorrelation between the levels of PD-1 and Tim-3 expression in tumor tissues and tumor adjacent tissues. The expressions of PD-1 and Tim-3 in tumor tissues and tumor adjacent tissues were significantly associated with PD-1 and Tim-3 polymorphisms, with genotype AA of PD-1 rs10204525 and genotypes GT + TT of Tim-3 rs10053538 respectively \[[@CR33]\]. LAG-3 is another important inhibitory immune check point and exerts synergistic effects with PD-1/PD-L1 on T cell activation in the tumor microenvironment. In HCC-vaccine-immunized mice, STAT3-blocked HCC vaccine downregulated expression of PD-1, TIGIT, and LAG-3, which could prevent cancer-induced dysfunction of CD8+ T and natural killer cells \[[@CR34]\]. Recently, expression of LAG3 was found to be significantly higher on tumor-associated antigen (TAA)-specific CD8+ tumor-infiltrating T helper cells and CD8+ cytotoxic T cells in tumors than those in tumor-free liver tissues and blood of HCC patients \[[@CR35]\]. Interestingly, blocking LAG-3 increased ex vivo proliferation of CD4+ and CD8+ TIL and effector cytokine production. Combination of LAG-3 blocking antibody with PD-L1 blockade further augmented TIL responses to polyclonal stimuli and TAA \[[@CR35]\]. This suggests that LAG-3 plays an important role in T-cell suppression in the HCC microenvironment and might be a promising immunotherapeutic target for HCC. Further clinical trials about Tim-3, Lag-3 or TIGIT blockers should be performed in liver cancer treatment.

Co-stimulatory immune checkpoints {#Sec6}
---------------------------------

The best characterized co-stimulatory ligands that have been investigated in hepatocellular carcinoma are B7-1 and B7-2. These two important immune checkpoints are mainly expressed on professional antigen-presenting cells. B7-1 and B7-2 can bind to both CD28 and CTLA-4, and thus regulate T cell activation via selective interacting with either CD28 or CTLA-4 \[[@CR36]\]. Expression of costimulatory molecules, including B7-1 and B7-2, have been found to be down-regulated in HCC cells \[[@CR37]\]. This down-regulation may lead to suppression of activation of effector T-cells mediated by B7/CD28. The glucocorticoid-induced tumor necrosis factor receptor (GITR) and the inducible T-cell co-stimulator (ICOS) are co-stimulatory checkpoints and regulate the immunosuppressive Tregs function. Importantly, GITR and ICOS are up-regulated in Tregs infiltrating HCC and may function as potential targets for immunotherapeutic interventions for antitumor therapy \[[@CR38]\].

Immune checkpoints and cholangiocarcinoma {#Sec7}
=========================================

Intrahepatic cholangiocarcinoma (ICC) represents the second most common primary liver malignancy, accounting for 10--20% of all primary liver cancers \[[@CR39]\]. Although ICC is traditionally viewed as a rare cancer, its incidence has been steadily rising, with recent reports showing the incidence of ICC in the USA has increased from 0.44 to 1.18 cases/100,000 over the past three decades \[[@CR40]\]. The prognosis for ICC continues to be poor, with surgery as the only definitive option for cure. Median survival rate is low because most patients are not eligible for curative resection. As such, there is an increasing need for the development of novel adjuvant therapies for patients with ICC.

PD-1/PD-L1 {#Sec8}
----------

In contrast to HCC, immunotherapy in cholangiocarcinoma has been limited and mostly ineffective \[[@CR41]\]. However, a high frequency of tumor-infiltrating lymphocytes and PD-L1 expression suggest that checkpoint inhibition may prove effective \[[@CR42]\]. Expression of PD-L1 was found both in tumor-associated macrophages and in the tumor front. Patients with tumors exhibiting PD-L1 expression around the tumor front had a lower overall survival than tumor front-positive patients \[[@CR43]\]. In 31 surgically resected ICC samples from Asian patients, PD-L1 expression was significantly higher in tumor tissue than that in adjacent tissue \[[@CR44]\]. High levels of PD-L1 expression were also found in Western patients with ICC, which resulted in tumor poor differentiation, higher malignant tumor stage and higher levels of apoptotic CD8+ TILs, and therefore led to lower chance of survival \[[@CR42]\]. More recently, in occupational cholangiocarcinoma, PD-L1 expression was found in biliary intraepithelial neoplasia and intraductal papillary neoplasm. Cholangiocarcinoma cells expressed PD-L1 in a low number of cases of occupational cholangiocarcinoma, while carcinoma cells expressed PD-L1 in all cases. Moreover, PD-L1 and PD-1 were also expressed in tumor-associated macrophages and tumor-infiltrating T cells expressed. The number of PD-L1-positive mononuclear cells, PD-1-positive lymphocytes, and CD8-positive lymphocytes infiltrating within the tumor was markedly high in occupational cholangiocarcinoma. Immunostaining with mAbs detected human leukocyte antigens (HLA) class I defects in 60% of ICC tumors and PD-L1 expression in 30%. Patients bearing tumors with HLA class I defects and PD-L1 expression had a significantly reduced survival rate. The results suggested PD-L1 up-regulation mediates immune escape in cholangiocarcinoma and could be potential biomarker of response to anti-PD-1/PDL1 immunotherapy \[[@CR45]\]. The role of other immune checkpoints for cholangiocarcinoma is still not well established.

Epigenetic mechanism in checkpoint immunotherapy {#Sec9}
================================================

In cancer, two important epigenetic mechanisms include hypermethylation, which is mediated by DNMTs, and histone deacetylation, which is mediated by HDACs. Epigenetic dysregulation is a crucial mechanism underlying the progression of cancer \[[@CR46]--[@CR49]\]. Some epigenetic regulators can act negatively and positively in immune responses and lead to immune evasion \[[@CR50]\], which provides a novel mechanism in immune checkpoint therapy for treatment of cancers.

Recently, epigenetic modifications of the key immune checkpoints including PD-1, PD-L1, and CTLA-4 were analyzed in non-small cell lung cancer tissues from 39 patients \[[@CR51]\]. It was shown that CTLA-4 and PD-1, but not PD-L1, are hypomethylated in human lung tumors. This hypomethylation also led to increased expression of these two genes as shown by transcriptome analysis \[[@CR51]\]. In a phase 2 trial, hypomethylating agents such as vorinostat and azacitidine upregulated mRNA expression of PD-L1, PD-L2, PD-1 and CTLA-4 in 61 patients with acute myeloid leukemia \[[@CR52]\]. More recently, profiling DNA methylation in peripheral blood mononuclear cells and T cells from HCC patients show that a broad signature of DNA methylation intensifies with progression of HCC \[[@CR53]\]. Importantly, HCC DNA methylation is highly enriched in immune function-related gene PD-1 \[[@CR53]\]. Interestingly, Liu et al. found highly upregulated DNA methyltransferase 1 (DNMT1) is positively correlated with PD-L1 overexpression in sorafenib-resistant HCC cells. PD-L1 further induced DNMT1-dependent DNA hypomethylation and restored the expression of methylation-silenced Cadherin 1, a metastasis suppressor in HCC \[[@CR54]\].

Accumulating evidence also shows histone deacetylation regulates immune checkpoint expression and plays an important role in cancer progression. HDAC is have been shown to sensitize cancer cells to immune checkpoint therapy by upregulating the immune checkpoints CTLA-4, PD-1, PD-L1, and PD-L2 on tumor cells and TILs \[[@CR55]\]. For example, inhibition of the class I HDAC1, HDAC2 and/or HDAC3 led to acetylation of the PD-L1 and PD-L2 promotors, which augmented up-regulation of PD-L1/L2 protein and RNA transcription in melanoma patients, in melanoma cell lines and in a syngeneic mouse model of melanoma \[[@CR56]\]. Interestingly, Lienlaf et al. \[[@CR57]\] found HDAC6i (ACY-241) reduced PD-L1 production and increased co-stimulatory checkpoint (CD28) levels, and thus suppressed tumor growth in vivo. In the WM164 HDAC6KD cells, the expression of PD-L2, B7-H4 and TRAIL-R1 were largely diminished, while B7-H3, Galectin-9 and TRAIL-R2 were moderately decreased. In breast cancer cells, CD137, a co-stimulatory checkpoint, was found to be up-regulated by HDACi (SAHA) treatment \[[@CR58]\]. Therefore, inhibitory and co-stimulatory checkpoints can be up-regulated or down-regulated by different HDAC isoforms in different tumor types. To date, the immune modulatory activity of HDAC inhibitors on tumor-specific immunity including immune checkpoints has not been well demonstrated or characterized in HCC.

Recent evidence suggests that noncoding RNAs, such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), may also have direct epigenetic functions by recruiting specific protein complexes to genomic DNA, and specifically to some promoters modulating the expression of the corresponding genes. MiRNAs and lncRNAs play important roles in regulating expression of immune checkpoints in various tumors \[[@CR59]\]. In human malignant pleural mesothelioma, the levels of miR-15b, miR-16, miR-193a-3p, miR-195, and miR-200c were significantly lower in the immune checkpoint PD-L1-positive samples. Likewise, PD-L1 and miR-138-5p levels were inversely correlated in human colorectal cancer tumors, and miR-138-5p inhibited PD-L1 expression in tumor models in vivo \[[@CR60]\]. In lung cancer, it was demonstrated that the p53/miR-34/PD-L1 and miR-200/ZEB1/PD-L1 axis are novel mechanisms in tumor immune evasion \[[@CR61], [@CR62]\]. Moreover, it is recently demonstrated that transfection of human CD4+ T cells with miR-138 suppressed expression of CTLA-4, PD-1, and Foxp3 in glioma preclinical models \[[@CR63]\]. Whether the association between miRNA expression and immune checkpoint levels in tumors can be translated into a predictive marker of checkpoint inhibitor therapy in liver cancer requires further investigation. Interactions among three kinds of RNAs were revealed in the 'lncRNA-miRNA-mRNA' competing endogenous RNA network. Several biomarkers were identified for diagnosis of diabetic pancreatic cancer, such as lncRNAs (HOTAIR, CECR7 and UCA1), hsa-miR-214, hsa-miR-429, CCDC33 and CTLA-4. Notably, interactions of 'CECR7-hsa-miR-429-CTLA4' were highlighted in the endogenous RNA network, which is very important in enhancing the progression of pancreatic cancer \[[@CR64]\]. Some miRNAs and lncRNAs might be involved in the "cancer immunity cycle" regulated by immune checkpoints such as CTLA-4 and PD-L1-PD-1 and could be the subject of future investigations in liver cancer.

Taken together, a wave of translational research highlights the mechanistic and functional link between epigenetic regulation and immune checkpoints in the development and progression of primary tumors including liver cancer.

Checkpoint-blocking based therapeutic approaches {#Sec10}
================================================

Over the last decade, there has been significant progress in our understanding of the immune system which has led to development of numerous immune checkpoints blockades that have altered the management and prognosis in some cancers including liver cancer (Table [2](#Tab2){ref-type="table"}). As more such drugs are developed, we will have multiple additional options and indications for these inhibitors in the near future. Among these pathways, the PD-1/PD-L1 and the B7-1/B7-2/CTLA-4 have been identified as clinically available inhibitors.

These immune checkpoint drugs such as nivolumab, pembrolizumab, and ipilimumab have already been FDA approved in non-small cell lung cancer, renal cell carcinoma, melanoma, Hodgkin lymphoma, and urothelial bladder cancer \[[@CR65]\]. Trials investigating immune checkpoint blockades in HCC and cholangiocarcinoma are in progress and early signals of efficacy have recently been reported (Table [3](#Tab3){ref-type="table"}). Encouraging clinical outcomes were reported from an ongoing phase I/II trial of the anti-PD-1 antibody nivolumab at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago \[[@CR66]\]. Waterfall plots showed that the tumor size decreased to some extent in all cohorts including uninfected, HBV-infected, and hepatitis C virus-infected HCC patients. It was significant and stable in the response to the treatment of nivolumab in HCC patients. In another recent ongoing trial of nivolumab treatment in HCC patients, nivolumab showed a manageable safety profile, including acceptable tolerability. The objective response rate was 20% (95% CI 15--26) in patients treated with nivolumab 3 mg/kg in the dose-expansion phase and 15% (95% CI 6--28) in the dose-escalation phase \[[@CR67]\]. Early data from the biliary tract cohort of Keynote-028 reported an objective response rate of 17% and a further 17% achieved stable disease in PD-L1 positive pretreated advanced cholangiocarcinoma \[[@CR68]\].Table 3Clinical trials with immune checkpoints therapy in liver cancersCancer typeNumberStudy armsStageStatusDesignPrimary outcomeEstimated completionTrial NCTHCC35Nivolumab (anti PD-1 Ab) + LRT (Yttrium 90Y glass microspheres)Phase 1RecruitingSingle Group AssignmentJuly 2019July 2019NCT02837029HCC154PDR001 (anti PD-1 Ab) + NIS793 (anti TGF-b Ab)Phase 1RecruitingNon-RandomizedJanuary 12, 2020January 12, 2020NCT02947165HCC114Durvalumab (anti PD-1L Ab) + ramucirumab (anti-VEGF-R2 Ab)Phase 1RecruitingNon-RandomizedMarch 2018September 2018NCT02572687HCC51Durvalumab (anti PD-1 L Ab) + AZD4635Phase 1RecruitingNon-RandomizedNovember 9, 2017November 9, 2017NCT02740985HCC61Tremelimumab (anti CTLA-4 Ab)Phase 1Active, not recruitingNon-RandomizedDecember 31, 2017December 31, 2018NCT01853618Liver cancer60Ipilimumab (anti CTLA-4 Ab) + MGN1703 (Toll-like receptor agonist)Phase 1RecruitingNon-RandomizedMay 2019May 2019NCT02668770HCC120Ipilimumab (anti CTLA-4 Ab) + stereotactic body radiationPhase 1RecruitingRandomizedAugust 2019August 2019NCT02239900HCC75Nivolumab (anti PD-1 Ab) + galunisertib (TGF-b inhibitor)Phase 1/2RecruitingNon-RandomizedApril 2018March 2019NCT02423343HCC620Nivolumab (anti PD-1 Ab) + ipilimumab (anti CTLA-4 Ab)Phase 1/2RecruitingNon-RandomizedJuly 22, 2018July 9, 2019NCT01658878HCC108PDR001 (anti PD-1 Ab) + INC280 (c-Met inhibitor)Phase 1/2RecruitingNon-RandomizedDecember 24, 2018December 24, 2018NCT02795429HCC50Prembrolizumab (anti PD-1 Ab) + dendritic cells, cytokine-induced killer cellsPhase 1/2RecruitingSingle Group AssignmentSeptember 2019October 2019NCT02886897HCC15Prembrolizumab (anti PD-1 Ab)Phase 1/2RecruitingSingle Group AssignmentDecember 2019December 2019NCT02940496HCC50Nivolumab (anti PD-1 Ab) + CC-122 (immunostimulatory pathway modifier)Phase 1/2RecruitingSingle Group AssignmentJune 23, 2020June 23, 2020NCT02859324HCC90Durvalumab (anti PD-1 L Ab), Tremelimumab (anti CTLA-4 Ab) + LRTPhase 1/2RecruitingNon-RandomizedApril 30, 2020April 30, 2021NCT02821754HCC620Nivolumab (anti PD-1 Ab), Nivolumab + Ipilimumab, Nivolumab + cabozantinib, Nivolumab + Ipilimumab + cabozantinibPhase 1/2RecruitingNon- RandomizedSeptember 4, 2018July 9, 2019NCT01658878HCC28Pembrolizumab (Keytruda) (anti PD-1 Ab)Phase 2RecruitingSingle Group AssignmentApril 2018April 2019NCT02658019HCC440Durvalumab (anti PD-1 L Ab) + Tremelimumab (anti CTLA-4 Ab)Phase 2RecruitingRandomizedMarch 20, 2020March 20, 2020NCT02519348HCC726Nivolumab (anti PD-1 Ab)Phase 3RecruitingRandomizedOctober 1, 2018June 22, 2019NCT02576509HCC408Prembrolizumab (anti PD-1 Ab)Phase 3Active, not recruitingRandomizedFebruary 1, 2019February 1, 2019NCT02702401HCC1200Durvalumab (anti PD-1 L Ab) + tremelimumab (anti CTLA-4 Ab)Phase 3Not yet recruitingRandomizedFebruary 27, 2020March 29, 2021NCT03298451

Immunotherapy is promising for HCC and cholangiocarcinoma. However, even for those patients who respond to the single agent immunotherapy, combinational therapy may be more potent and lead to more durable response. At the 2016 ASCO meeting, an ongoing phase I trial showed trans catheter arterial chemoembolization. Radiofrequency, or cryoablation induced a peripheral immune response which may enhance the effect of anti-CTLA-4 treatment. This combination is safe and leads to the accumulation of intratumoral CD8+ T cells and activation of T cells in peripheral blood in responding patients. Encouraging clinical activity was seen with objective confirmed responses and a PFS of 5.7 months (NCT01853618) \[[@CR65]\]. Another pilot study for the combined effect of immune checkpoint blocking and ablative therapies has been initiated in patients with advanced liver cancer (NCT02821754). Chemotherapy such as cisplatin can reduce PD-L2 expression on tumor cells \[[@CR69], [@CR70]\]. Both these studies show that chemotherapy can enhance antitumor immunity and thus may combine and augment immune checkpoint therapy for treatment of liver cancer.

As previously discussed, epigenetic modulators enhance cell surface expression of immune checkpoints. Several studies provided evidence to support increased expression of checkpoint inhibitors on tumor cells following epigenetic treatment, which enhances responses to immune checkpoint therapy \[[@CR56], [@CR71]\]. Recently, the role of HDACi and histone methyltransferases in tumor immunity and cancer therapy has been investigated. In melanoma-bearing mice, HDACi upregulated expression of PD-L1 and PD-L2 through increased histone acetylation. Further, combination of HDACi and PD-1 blockade led to higher efficiency in slowing tumor progression and improving survival rate than single agent therapy \[[@CR56]\]. 3-Deazaneplanocin A and 5-aza-2′deoxycytidine, two important DNMTi, enhanced the therapeutic efficacy of PD-L1 blockade in reducing tumor volume, increasing tumor infiltrating CD8+ T cells and Th1-type chemokine expression in ovarian cancer in C57/BL6 mice \[[@CR72]\]. Chiappinelli et al. demonstrated that 5-azacytidine, sensitized tumors to anti-CTLA-4 immune checkpoint therapy compared to 5-azacytidine or anti-CTLA-4 alone in a mouse model of melanoma \[[@CR73]\]. Enhancer of zeste homolog 2 blockade led to reduced PD-L1 mRNA levels and a decrease in PD-L1+ Pax3+ in melanoma cells, which was maintained during concomitant IL-2cx or anti-CTLA-4 immunotherapy \[[@CR74]\]. Taken together, these discoveries create a highly promising basis for combination studies using epigenetic and immune checkpoint therapy in patients with various cancers including liver cancer (Table [4](#Tab4){ref-type="table"}).Table 4Ongoing clinical trials combining epigenetic drugs and immune checkpoint blockade therapy in cancersCancer typeNumberImmune checkpoint inhibitorsEpigenetic drugsStageStatusDesignTrial NCTHCC90DurvalumabGuadecitabinePhase 1RecruitingSingle Group AssignmentNCT03257761Unresectable NSCLC41Nivolumab and ipilimumabACY-241Phase 1RecruitingSingle Group AssignmentNCT02635061Metastatic unresectable HER2-negative breast cancer45PembrolizumabEntinostatPhase 1RecruitingSingle Group AssignmentNCT02453620Advanced solid tumors30PembrolizumabEntinostatPhase 1RecruitingRandomizedNCT02909452Unresectable stage III/IV melanoma17IpilimumabPanobinostatPhase 1RecruitingSingle Group AssignmentNCT02032810Advanced CRC30PembrolizumabRomidepsin and/or 5-AZAPhase 1RecruitingRandomizedNCT02512172MSS advanced CRC30PembrolizumabRomidepsin and/or 5-AZAPhase 1RecruitingRandomizedNCT02512172MDS following DNMTi-failed therapy27PembrolizumabEntionstatPhase 1RecruitingSingle Group AssignmentNCT02936752Advanced solid tumors or lymphomas45NivolumabRRx-001Phase 1Active, not recruitingSingle Group AssignmentNCT02518958MM19IpilimumabSGI-110Phase 1RecruitingSingle Group AssignmentNCT02608437MDS73Durvalumab with or without tremelimumabAzacytidinePhase 1RecruitingNon-RandomizedNCT02117219Advanced cell carcinoma62AtezolizumabEntinostatPhase 1/2RecruitingSingle Group AssignmentNCT03024437Breast cancer88AtezolizumabEntinostatPhase 1/2RecruitingRandomizedNCT02708680DLBCL5RituximabBelinostatPhase 2Active, not recruitingSingle Group AssignmentNCT01686165Metastatic uveal melanoma29PembrolizumabEntinostatPhase 2RecruitingSingle Group AssignmentNCT02697630DLBCL42RituximabPanobinostatPhase 2Active, not recruitingRandomizedNCT01238692Advanced solid tumors and NSCLC119DurvalumabMocetinostatPhase 1/2RecruitingSingle Group AssignmentNCT02805660NSCLC and melanoma202PembrolizumabEntinostatPhase 1/2RecruitingNon-RandomizedNCT02437136HNSCC and SGC49PembrolizumabVorinostatPhase 1/2Active, not recruitingSingle Group AssignmentNCT02538510Stage IV NSCLC100PembrolizumabVorinostatPhase 1/2RecruitingRandomizedNCT02638090DLBCL83RituximabVorinostatPhase 1/2Active, not recruitingSingle Group AssignmentNCT00972478Lymphoma/leukaemia40RituximabVorinostatPhase 1/2Active, not recruitingSingle Group AssignmentNCT00918723Advanced renal or urothelial cell carcinoma42PembrolizumabVorinostatPhase 2RecruitingNon-RandomizedNCT02619253Hormone therapy-resistant breast cancer87PembrolizumabVorinostatPhase 2RecruitingRandomizedNCT02395627AML182Nivolumab5-AZAPhase 2RecruitingNon-RandomizedNCT02397720Metastatic CRC31Nivolumab5-AZAPhase 2Active, not recruitingSingle Group AssignmentNCT02260440Advanced/metastatic NSCLC100Nivolumab5-AZAPhase 2Active, not recruitingRandomizedNCT02546986MDS120Nivolumab and/or ipilimumab5-AZAPhase 2RecruitingNon-RandomizedNCT02530463Refractory/relapsed AML37Lirilumab5-AZAPhase 2Active, not recruitingSingle Group AssignmentNCT02399917MDS12Lirilumab and nivolumab5-AZAPhase 2Active, not recruitingNon-RandomizedNCT02599649Metastatic melanoma71Pembrolizumab5-AZAPhase 2RecruitingNon-RandomizedNCT02816021NSCLC120Nivolumab5-AZA and/or entinostatPhase 2RecruitingRandomizedNCT01928576NSCLC60Nivolumab5-AZA- CdR/tetrahydrouridinePhase 2RecruitingRandomizedNCT02795923Advanced solid tumors60Durvalumab5-AZAPhase 2RecruitingSingle Group AssignmentNCT02811497Advanced/metastatic NSCLC100PembrolizumabOral azacytidinePhase 2Active, not recruitingRandomizedNCT02546986PR recurrent OC38PembrolizumabGuadecitabinePhase 2RecruitingSingle Group AssignmentNCT02901899PR recurrent OC20PembrolizumabOral azacytidinePhase 2RecruitingRandomizedNCT02900560MDS120DurvalumabOral azacytidinePhase 2RecruitingRandomizedNCT02281084MDS, AML213DurvalumabAzacytidinePhase 2Active, not recruitingRandomizedNCT02775903Refractory/recurrent epithelial OC138AvelumabEntinostatPhase 2RecruitingRandomizedNCT02915523DLBCL304Rituximab5-AZAPhase 3RecruitingRandomizedNCT02951156*HCC* hepatocellular carcinoma, *NSCLC* Non-small cell lung cancer, *HER2* human epidermal growth factor receptor 2, *CRC* colorectal cancer, *5-AZA* Azacitydine, *MSS* Microsatellite stable, *MDS* Myelodysplastic syndromes, *DNMTi* DNA methyltransferase inhibitor, *MM* Multiple myeloma, *DLBCL* Diffuse large B cell lymphoma, *HNSCC* head and neck squamous cell carcinoma, *SGC* salivary gland cancer, *AML* Acute myeloid leukaemia, *OC* ovarian cancer

Combination therapy with immunotherapy and chemotherapy or radiation therapy are being studied and reported to be synergistic through multiple mechanisms. As more data of these combinations is available, it will likely improve outcomes for patients with this rare aggressive group of cancers, and we will also be able to develop further trials to upgrade our understanding of therapies targeting liver cancers. Therefore, immunotherapy offers hope to liver cancer patients with a dismal prognosis that has not seen significant changes in therapy for a long time.

Limitations and perspectives of immune checkpoint therapy {#Sec11}
=========================================================

Resistance to immune checkpoint blockades is still commonly observed in most cancer patients \[[@CR75]\]. Failure of immune checkpoint inhibitors therapy can result from three categories: (1) mutations of the immunogenicity of cancer itself. The mutations influence expression of components of antigen-processing and presentation machinery (e.g., transporter associated with antigen processing, HLA class molecules, and β2 microglobulin), novel tumor-associated antigens (e.g., cancer-testis antigens, neoantigens), and cytokines; (2) expression of alternative immune checkpoint ligands on tumor cells (and/or immune cells). Expression of alternative co-inhibitory immune checkpoints (e.g., CTLA-4, TIM-3, LAG-3, and VISTA) has been associated with resistance to PD-1 blockade \[[@CR76], [@CR77]\]; or (3) defects in T cell infiltration. Diminished infiltration of T cells led to resistance to PD-1 blockade in melanoma patients \[[@CR78]\]. However, epigenetic modifying agents including demethylating agents and histone deacetylase inhibitors may enable re-expression of immune related therapeutic genes, especially in combination of immunotherapy \[[@CR79], [@CR80]\]. They can also increase expression of immune checkpoints to synergize with immune checkpoint blockade therapy, leading to improving anti-tumor responses \[[@CR81]\].

Conclusions {#Sec12}
===========

Most liver cancers are diagnosed at an advanced stage, while the therapy is limited. Immune checkpoint therapy provides survival benefit for liver cancer treatment. Epigenetic regulation mechanistically and functionally links with immune checkpoints. Epigenetic mechanisms of checkpoint blocking prove to be promising in treating liver cancers and determining patient prognosis. Further investigations are required to explore the clinical potential in combination with epigenetic and immune checkpoint therapy for liver cancer treatment.

APC

:   Antigen presenting cell

ASCO

:   American Society of Clinical Oncology

BTLA

:   B- and T-lymphocyte attenuator

CTLA-4

:   Cytotoxic T lymphocyte--associated antigen 4

DNMT1

:   DNA methyltransferase 1

DNMTi

:   DNA methyltransferase inhibitors

GITR

:   Glucocorticoid-induced tumor necrosis factor receptor-related gene

HBV

:   Hepatitis B virus

HCC

:   Hepatocellular carcinoma

HDACi

:   Histone deacetylase inhibitors

HLA

:   Human leukocyte antigens

HVEM

:   Herpesvirus entry mediator

ICC

:   Intrahepatic cholangiocarcinoma

IDO

:   Indoleamine 2,3-dioxygenase

KIRs

:   Killer cell immunoglobulin-like receptors

LAG-3

:   Anti-lymphocyte activation gene-3

lncRNAs

:   long noncoding RNAs

miRNAs

:   microRNAs

PD-1

:   Programmed cell death protein-1

PD-L1

:   Programmed cell death ligand 1

TAA

:   Tumor-associated antigens

TAM

:   Tumor-associated macrophages

TILs

:   Tumor-infiltrating lymphocytes

Tim-3

:   T-cell immunoglobulin- and mucin-domain-containing molecule-3

Tregs

:   Regulatory T cells

VISTA

:   V-domain Ig suppressor of T-cell activation

The authors acknowledge the contribution of all investigators at the participating study sites.

Funding {#FPar1}
=======

This work was supported by Shenyang Science and Technology Project (No. 17-230-9-16).

FX, YZ and CD contributed to study conception and design. FX and TJ wrote the main manuscript text and prepared the figures and Tables. YZ and CD provided advice regarding the paper. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar2}
==========================================

Not applicable

Competing interests {#FPar3}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar4}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
